On Mar. 20, 2023, NIH scientists announced that the magnitude and quality of a key immune cellﾒs response to vaccination with two doses of the Pfizer-BioNTech COVID-19 vaccine were considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, a study had found.

The magnitude and quality of a key immune cellﾒs response to vaccination with two doses of the Pfizer-BioNTech COVID-19 vaccine were considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, a study has found.